TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / BillionToOne Stock

BillionToOne Stock

billiontoone.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $213.55MM

BillionToOne is a molecular counter platform designed to accurately count DNA molecules to the single-count level. With a mission to detect disorders such as cystic fibrosis and sickle-cell disease, the company optimizes the signal-to-noise ratio through blood testing. The platform specializes in both prenatal and oncology divisions. BillionToOne was founded by David Tsao, Oguzhan Atay, and Sukrit Silas in 2016 and is headquartered in San Francisco, CA.

Buy or sell BillionToOne stockLearn more about BillionToOne IPO

Register To Buy and Sell Shares

For more details on financing and valuation for BillionToOne, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access BillionToOne’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BillionToOne.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

BillionToOne investors also invested in these private companies

Y Combinator
Adams Street Partners
Northwest Venture Partners
Hemisphere Ventures
Four Rivers Group
Fifty Years
500 Global
UpHonest Capital
Time BioVentures
Start Capital
Metaplanet Holdings
Neotribe Ventures
HOF Capital
Hummingbird Ventures
U.S. Department of Health and Human Services
Civilization Ventures
NewDo Venture
QB3

Team

Management Team

Oguzhan Atay Ph.D
Co-Founder
David Tsao Ph.D
Co-Founder

Frequently Asked Questions About BillionToOne’s Stock

plusminus
Can you buy BillionToOne’s stock?
BillionToOne is not publicly traded on NYSE or NASDAQ in the U.S. To buy BillionToOne’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell BillionToOne’s stock?
Yes, you can sell stock of a private company like BillionToOne. Forge can help you sell your BillionToOne stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is BillionToOne’s stock price?
BillionToOne is a privately held company and therefore does not have a public stock price. However, you may access BillionToOne’s private market stock price with Forge Data.
plusminus
What is BillionToOne’s stock ticker symbol?
BillionToOne does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like BillionToOne in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Silicon Valley Daily 12/27/2022
BillionToOne Scores $48.5 Million - Silicon Valley Daily
BillionToOne, Inc., a molecular diagnostics company, has secured an additional $48.5 million of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to $35 million, with its existing lender, Bridge Bank.

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.